Pasithea Therapeutics Corp. Form 8-K Summary
Business context and reporting period
Pasithea Therapeutics Corp. filed a Form 8-K dated November 24, 2021, with the closing of the reported offering occurring on November 29, 2021. The filing reports a private placement of equity securities and related agreements. The company is an emerging growth company with common stock and warrants listed on Nasdaq.
Transaction and key financial metrics
- The company sold 8,680,000 shares of common stock and warrants to purchase an additional 8,680,000 shares.
- The combined price for each share and associated warrant was $3.50, implying gross proceeds of approximately $30.38 million.
- The warrants are immediately exercisable, have a five-year term, and an exercise price of $3.50 per share, subject to adjustment provisions.
- Warrants may be exercised on a cashless basis if the underlying shares are not covered by an effective resale registration statement.
- Investors may elect ownership limitations restricting exercise if their holdings would exceed either 4.99% or 9.99% of outstanding common stock.
- Placement-agent compensation includes a 9.0% cash fee, a 1.0% non-accountable expense fee, and reimbursement of up to $70,000 of accountable expenses. Based on gross proceeds, the two percentage-based fees total approximately $3.04 million, before the additional expense reimbursement and other offering costs.
- The filing does not provide revenue, profit, cash-flow, margin, debt, or liquidity balances for a reporting period.
Material changes versus the prior comparable period
The filing does not present comparative operating or financial results. The material reported change is the company’s approximately $30.38 million private financing, together with the issuance of securities potentially representing 8,680,000 additional common shares upon warrant exercise.
Use of proceeds, outlook, and risks
- Net proceeds are intended to fund preclinical research and development for future product candidates, development of the company’s U.S. and U.K. clinic businesses, working capital, and general corporate purposes.
- The company agreed to file a resale registration statement covering the shares, warrants, and warrant shares promptly after closing and no later than 15 calendar days after the registration rights agreement’s effective date.
- The company must seek effectiveness by the applicable deadline and maintain the registration statement. Failure to meet these obligations may result in liquidated damages payable to investors.
- For specified periods after the registration statement becomes effective, the company is restricted from issuing additional common stock or common-stock equivalents and from entering into certain variable-rate transactions.
- The securities were issued in reliance on the private-placement exemption under Section 4(a)(2) of the Securities Act and Regulation D and were not registered at issuance.
- Key risks include potential dilution from warrant exercises, future financing restrictions, registration-related liquidated damages, use-of-proceeds execution risk, and the company’s reliance on preclinical and clinic-development initiatives.
Important facts for investors to verify
- Confirm the final net proceeds after placement-agent fees, expense reimbursement, and other offering costs.
- Review the warrant adjustment, cashless-exercise, expiration, and ownership-limitation provisions.
- Verify the filing and effectiveness dates of the resale registration statement and any liquidated damages incurred.
- Assess the number of common shares outstanding before and after the offering and the potential dilution from the warrants.
- Review subsequent filings for use of proceeds, liquidity, operating results, additional financings, and any changes to the company’s clinic or preclinical programs.